AI Article Synopsis
- A 35-year-old woman with autoimmune-mediated neuropathic postural tachycardia syndrome (PoTS) showed improvement after receiving immunoglobulin therapy.
- Initial treatment with intravenous immunoglobulin (IVIg) caused some side-effects, but she tolerated subcutaneous immunoglobulin (SCIg) better, leading to significant clinical improvement.
- The reduction in serum antibody levels over 22 months after the first IVIg infusion suggests that autoimmune-mediated PoTS can be effectively managed with IVIg, while SCIg minimizes side effects.
Article Abstract
Aims: We describe the disease course of a 35-year-old female with an autoimmune mediated neuropathic postural tachycardia syndrome (PoTS), who responded to immunoglobulin therapy and stabilized on maintenance therapy with subcutaneous immunoglobulin (SCIg).
Methods: We provide longitudinal data of clinical scores, tilt-table results and antibody titers.
Results: Initial treatment with intravenous immunoglobulin caused infusion-related side-effects whereas SCIg was well tolerated and improved clinical symptoms and quality of life. Clinical improvement correlated with the reduction of serum antibody titers 22 months after first infusion.
Conclusions: These findings suggest that autoimmune-mediated neuropathic PoTS can be treated sufficiently with IVIg whereas SCIg minimizes side-effects.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8387908 | PMC |
| http://dx.doi.org/10.1016/j.jtauto.2021.100112 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!